Study Phase 2

A Phase II, Multicenter, Randomized, Double-Blind, Placebo Controlled Study Evaluating the Efficacy and Safety of Anti-TNF a Monoclonal Antibody (Infliximab) to Treat Cancer-Related Cachexia in Subjects With Pancreatic Cancer

Trial Information

Generic NameInfliximabProduct NameREMICADE®Therapeutic AreaImmune System DiseasesEnrollment73% Female46.1%% White98.9%
Product ClassAntirheumatic Agents - Biologic Response ModifiersSponsor Protocol NumberC0168T60Data PartnerJohnson & JohnsonCondition StudiedCachexiaMean/Median Age (Years)63.1

Supporting Documentation

  • Collected Datasets Available
  • Data Definition Specification Available
  • Protocol with Amendments Available
  • Statistical Analysis Plan Available
  • Clinical Study Report Available

Disclaimer

Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.